StockUS listing USALZNNASDAQHealthcareCapital Destroyer

Alzamend Neuro Inc(ALZN) Stock Analysis | Healthcare

USD --+0.00%
Reward30Low
Risk45Moderate
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 3.74M
Reward Ratingⓘ30 Low reward assessment · 75% data coverage
Bottom 1% of stocksView factors
Risk Ratingⓘ45 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ALZN to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Alzamend Neuro Inc?

, a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.

AI Brief Pro

The brief on Alzamend Neuro Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Alzamend Neuro Inc?

, a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.74M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (30)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.432
Insider Activity
12M windowMixed
Shares soldShares bought
0-3months
12,000 shares
$3k
0
3-6months
0
0
6-9months
0
1108,388 shares
$109k
9-12months
25,184 shares
$11k
0